Dare Bioscience announces grant to develop non-hormonal contraceptive candidate

Dare Bioscience (DARE) announced it entered into a grant agreement with the Bill & Melinda Gates Foundation for a grant of up to approximately $10.7M to fund activities related to the identification and development of a novel non-hormonal intravaginal contraceptive product candidate and to add additional clinical sites to accelerate the ongoing Ovaprene(R) pivotal study. “We are thrilled to receive this grant and to see the foundation’s continued commitment to invest in non-hormonal contraceptive methods,” said Sabrina Martucci Johnson, President and CEO at Dare Bioscience. “We believe that we are the right organization to move these innovative programs forward, given our extensive experience in the contraceptive space; in particular with novel non-hormonal product development, and our proven ability to advance development of differentiated product candidates that fulfill unmet needs in women’s health.”